JUST IN: SEC approves Nasdaq rule allowing the exchange to delist companies valued below $5 million after 30 consecutive days.
x.com/i/status/2080097928882884…
The only out is a Hearings Panel exception of up to 180 days, and only if the company can demonstrate it meets the higher initial listing standards. (Bloomberg) Pair it with the December change: Nasdaq can now immediately delist any security that fails to hold a $0.10 closing bid for 10 consecutive days.
What this means for the OTC — it's a supply event:
1. A delisting wave flows downhill. Nearly 180 Nasdaq companies currently sit below $5M cap, roughly a third of them Asia-based, (Bloomberg Law) and they don't vanish — they land on OTC (Expert Market or Pink, then some claw to OTCQB). The OTC is about to absorb a cohort of SEC-reporting, recently-audited companies. Structurally cleaner than the native OTC population: real filings, known share counts, some with residual institutional holders forced to sell.
2. Quality bifurcation. The OTC splits harder into two markets: a growing "fallen angel" tier that looks and files like small Nasdaq, and the legacy Pink/shell layer. Capital, data coverage, and broker access concentrate on the first tier. OTCQB/OTCQX gain legitimacy almost by accident — they become the de facto small-cap exchange America no longer has.
3. Liquidity and infrastructure follow. More real companies means more volume, more market-maker participation, more institutional tolerance for holding OTC paper, and pressure on brokers who currently restrict OTC trading to loosen up. OTC Markets Group itself is the cleanest beneficiary.
4. The gravity reverses. Historically the OTC was a waiting room for uplisting. With the Nasdaq floor raised and no cure period, uplisting becomes riskier and staying OTC becomes rational for sub-$50M companies. The OTC shifts from transit lounge to destination.
5. Regulation follows the migration. Regulators just pushed the "manipulation-prone" population from an exchange they control tightly onto a market they control loosely. That's not an endpoint — it's a setup. Expect tightened OTC rules (disclosure, promo policing, Expert Market expansion) within a couple of years, because the stated fraud rationale travels with the companies.
Net: short-term, the OTC gets bigger, more liquid at the top tier, and richer in tradeable dislocations - forced sellers, panic raises, shell conversions.
But we have the edge in the OTC we been here so we understand the landscape. Our filing forensics gets more valuable because the incoming cohort actually has filings to read.
We need to prepare for the shift and be ready to put our DD into full throttle looking now to see which tickers will land in our backyard.
